Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AlloVir (ALVR) shares

Learn how to easily invest in AlloVir shares.

AlloVir is a biotechnology business based in the US. AlloVir stocks (ALVR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $20.91 – a decrease of 17.01% over the previous week. AlloVir employs 110 staff and has a market cap (total outstanding stock value) of $677.5 million.

How to buy shares in AlloVir

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ALVR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

AlloVir stock price (NASDAQ:ALVR)

Use our graph to track the performance of ALVR stocks over time.

AlloVir shares at a glance

Information last updated 2022-01-17.
Latest market close$8.49
52-week range$9.92 - $47.00
50-day moving average $16.87
200-day moving average $20.42
Wall St. target price$42.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.23

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy AlloVir stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

AlloVir price performance over time

Historical closes compared with the close of $8.49 from 2022-01-20

1 week (2022-01-14) -18.37%
1 month (2021-12-21) -40.96%
3 months (2021-10-21) -65.63%
6 months (2021-07-21) -53.91%
1 year (2021-01-21) -81.15%
2 years (2020-01-17) N/A
3 years (2019-01-17) N/A
5 years (2017-01-17) N/A

AlloVir financials

Gross profit TTM $165,000
Return on assets TTM -24.54%
Return on equity TTM -43.42%
Profit margin 0%
Book value $4.45
Market capitalisation $677.5 million

TTM: trailing 12 months

AlloVir share dividends

We're not expecting AlloVir to pay a dividend over the next 12 months.

AlloVir overview

Allovir, Inc. , a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site